Mitsubishi Tanabe Pharma

December 9, 2021
img: Featured

In March 2015, Neurocrine Biosciences entered into an exclusive collaboration and licensing agreement with Mitsubishi Tanabe Pharma for the development and commercialization of valbenazine in Japan and other select Asian markets.

Mitsubishi Tanabe Pharma will be responsible for all development, marketing, and commercialization costs in their territories, and Neurocrine Biosciences will be entitled to a percentage of sales by Mitsubishi Tanabe Pharma. Neurocrine Biosciences retains full commercial rights to valbenazine in North America, Europe, and other countries outside of Asia.